The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute myocardial infarction (AMI) and unstable angina, an aging global population ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...